the official website of the antibody society
For World Cancer Day 2024, The Antibody Society has prepared a snapshot of the clinical development of therapeutic antibodies for cancer indication.
The infographic gives an overview on the trends in first in human studies and approvals, as well as on the active early and late stage pipelines (as of January 2024).
Need insights into the early-stage antibody therapeutics pipeline? We’ve got you covered! Join us Tuesday Oct 24th for an in-depth analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
Abstract: Since 2014, the number of antibody therapeutics entering clinical development annually has increased steadily, from 71 in 2014 to 286 in 2022. This has resulted in a clinical pipeline currently composed of ~1250 molecules, of which ~1100 and ~150 molecules are in early- and late-stage development, respectively. Despite the great interest in trends in early-stage clinical development, due to the difference in scale and difficulty in tracking molecules newly entered in clinical studies, analyses of trends in the global commercial development of antibody therapeutics are often limited to the late-stage clinical pipeline only. Luckily, The Antibody Society meticulously collects data for antibody therapeutics at all stages of clinical development. This webinar will provide an exhaustive analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
Our student winner is:
Mr. Matheus Oliveira De Souza (Ragon institute of MGH, MIT and Harvard, MIT, The University of Kansas)
Poster title: Enhanced antibody recognition against HIV resistant strains by directed evolution
Our post-doc winner is:
Dr. Nayara Braga Emidio (National Institutes of Health (NIH))
Poster title: Generation of neurokinin receptor ligands with specialized signalling properties via nanobody conjugation
The Antibody Society sponsors competitions each year to recognize and encourage the research activities of promising student/postdoctoral fellows. For the Research Competition, participants submitted a summary of their work on a topic related to antibody research. Winners (1 student and 1 post-doc) were selected based on originality, creativity, scientific merit, clarity of their research and its presentation.
Winners will receive:
Information on past competitions and winners can be found here.
mAbs is the official journal of The Antibody Society. Each year, the journal’s publisher, Taylor & Francis, provides several article publishing charge (APC) waivers, with a value of up to $4000 USD / £3200 / €3840 / $5570 AUD each, that we may distribute to members. To be considered for an APC waiver, please submit pre-submission inquiries, which should include the authors, title, abstract, and general outline of the intended article, to membership@antibodysociety.org.
mAbs publishes high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:
The selected recipients will be notified as soon as possible after the request submission deadline.
Please contact Janice Reichert (janice.reichert@antibodysociety.org) if you have questions.
Further information:
mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.
The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year.
Members of The Antibody Society receive a 10% discount on article publication charges using their member code.
Please note: Victor Greiff presented unpublished material; posting of the video of his talk will be delayed. Please subscribe to our YouTube channel to receive an alert when new videos are added.
Thank you for your interest in the Symposium. We hope the videos inspire useful discussions in the future.
